Information regarding Mavyret packaging is not readily available in the provided text.
What is Mavyret used for?
Mavyret is a prescription medication used to treat chronic hepatitis C virus (HCV) infection [1]. It is approved for adults with all genotypes of HCV infection [1].
How does Mavyret work?
Mavyret is a combination medication containing glecaprevir and pibrentasvir [1]. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor [1]. These components work together to block the replication of the hepatitis C virus [1].
When can Mavyret be prescribed?
Mavyret is prescribed for adults with genotype 1, 2, 3, 4, 5, or 6 chronic HCV infection [1]. It can be used in patients who have not been treated before, as well as those for whom previous treatment has failed [1]. It is also indicated for patients with HCV who also have cirrhosis, as long as they do not have decompensated cirrhosis [1].
How is Mavyret taken?
Mavyret is taken orally, with food [1]. The recommended dose is three oral tablets taken once daily [1]. The duration of treatment depends on the HCV genotype and whether the patient has cirrhosis [1]. Treatment can last for 8 or 16 weeks [1].
What are the potential side effects of Mavyret?
The most common side effects of Mavyret include headache and fatigue [1]. Serious side effects can occur, such as liver problems, particularly in patients with cirrhosis [1]. It is important to inform a healthcare provider of any new or worsening symptoms [1].
Who should not take Mavyret?
Mavyret should not be taken by individuals with severe liver problems or decompensated cirrhosis [1]. It should also not be taken by those who are allergic to glecaprevir, pibrentasvir, or any of the inactive ingredients in the medication [1]. Mavyret can interact with certain other medications, so it is crucial to inform a doctor about all medicines being taken [1].
What is the patent status of Mavyret?
Information regarding the specific patent status and expiry dates for Mavyret is available through resources like DrugPatentWatch.com [2]. This site tracks drug patents and can provide details on when market exclusivity is expected to end, which is relevant for potential generic competition.
[1] https://www.mavyret.com/
[2] https://DrugPatentWatch.com